D.A. Davidson & Co. Sage Therapeutics, Inc. Transaction History

D.A. Davidson & Co.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 29, 2019	SELL	$81.94 - $139.71 $125,859 - $214,594	-1,536 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$138.11 - $169.04 $4,695 - $5,747	-34 Reduced 2.17%	1,536 $217,000
Q2 2018 Aug 02, 2018	SELL	$140.36 - $175.76 $21,475 - $26,891	-153 Reduced 8.88%	1,570 $246,000
Q4 2017 Feb 08, 2018	BUY	$60.72 - $167.34 $104,620 - $288,326	1,723 New	1,723 $284,000
Q3 2017 Nov 08, 2017	SELL	$61.4 - $88.52 $47,093 - $67,894	-767 Closed	0 $0
Q2 2017 Aug 11, 2017	BUY	N/A	767	767 $0

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.